# RedHill Biopharma Ltd. (RDHL)

Source page: https://stoqly.net/companies/rdhl

- **Ticker:** RDHL (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001553846
- **Latest annual report:** 20-F filed 2026-04-27 (https://www.sec.gov/Archives/edgar/data/1553846/000110465926049055/rdhl-20251231x20f.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $0.39 on 2026-10-30
- **Revenue (FY2025):** $0.3M
- **Revenue growth:** −96.4%
- **Revenue growth, 5-year CAGR:** −66.2%
- **Operating margin:** −2,776.9%
- **Net margin:** −150.0%
- **Free cash flow:** −$9.7M
- **Free cash flow margin:** −3,376.2%
- **Change in share count:** +156.4%
- **Piotroski F-score:** 1/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/rdhl/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 0 | 4 | 8 | 6 | 64 | 86 | 62 | 7 | 8 | 0 |
| Operating income | -31 | -52 | -39 | -43 | -64 | -81 | -43 | -10 | -6 | -8 |
| Net income | -29 | -46 | -39 | -42 | -76 | -98 | -72 | 24 | -8 | 0 |
| Diluted EPS (US$) | -0.24 | -0.26 | -0.17 | -0.14 | -0.21 | -0.21 | -0.12 | 0.01 | 0.00 | 0.00 |
| Operating cash flow | -28 | -45 | -34 | -41 | -49 | -65 | -29 | -36 | -9 | -10 |
| Free cash flow | -28 | -45 | -34 | -41 | -49 | -65 | -29 | -36 | -9 | -10 |
| Cash | 54 | 16 | 29 | 29 | 29 | 29 | 20 | 6 | 5 | 4 |
| Debt and leases | — | — | — | — | 81 | 84 | 115 | — | — | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.